Article Text
PDF
Abstract
Introduction/Background Survival of ovarian carcinoma has improved in recent years due to determination of the homologous recombination deficit (HRD), and the use of first-line maintenance with PARP inhibitors (PARPi).
The aim of our study was to do a real world study in patients treated in our Center.
Methodology A cross-sectional longitudinal observational study was designed in a cohort of 100 patients diagnosed with ovarian cancer during the period 2018 to 2022. HRD was determined by Myriad myChoice test. The variables to be studied were: somatic mutation, and germline if positive by NGS, type of mutation, age at diagnosis, histology, stage, primary or interval surgery after neoadjuvant chemotherapy, response, PARPi, progression free survival (PFS), and allergy to chemotherapy.
Results The mean age at diagnosis of ovarian carcinoma was 62 years, with a predominance of 50% stage IIIC, and 80% of serous histology grade 3. 32% were HRD positive, with BRCA1 in 55%, BRCA2 in 10%, and the remaining 35% others of the RAD51C, BRIP1.
68% of cases received neoadjuvant chemotherapy, and only 50% were candidates for interval surgery. Primary surgery was performed in 32% of patients. Results: CR 38.4%, PR 53.5%. SD: 2% and progression 6.1%. Allergic reaction to chemotherapy occurred in 22% of the total.
38% of patients received PARPi as first-line maintenance.
In the group of patients who progressed to first line (49% of our series), PFS was higher in those with somatic line pathogenic variants, presenting a median of 18 months versus 10 months, (p=0.015).
Conclusion The results of our case series are compatible with those published in the literature, highlighting the increase in PFS in HRD+ patients who have received maintenance with PARPi. We found an increase of allergic reactions in patients carrying pathogenic germline variants, probably due to splicing-related mechanisms. These data should be cross-checked with other future studies.
Stage/Progression. PFS/HRD
Disclosures No